Citations

Mayo Clinic

Showing 10 of 108523 citations.

Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma
Wang, Jacqueline , Wang, Jacqueline F , Wang, Yucai

Expert Review of Hematology | August 7, 2024 | Volume: 17 | Issue: 10 | Pages: 651-659

10.1080/17474086.2024.2389993 | PMID 39109468 Get It

The Effects of Aspirin Intervention on Inflammation-Associated Lingual Bacteria: A Pilot Study from a Randomized Clinical Trial
Onyeaghala, Guillaume C. , Sharma, Shweta , Oyenuga, Mosunmoluwa , Staley, Christopher , Demmer, Ryan T. , Thyagarajan, Bharat , Straka, Robert J. , Church, Timothy R. , Prizment, Anna E. , Staley, Christopher M , Thyagarajan, Bharat , Straka, Robert J , Church, Timothy R , Prizment, Anna E , Demmer, Ryan T , Milne, Ginger L. , Shaukat, Aasma

Microorganisms | August 7, 2024 | Volume: 12 | Issue: 8 | Pages: 1609

10.3390/microorganisms12081609 | PMID 39203451 Get It

Several bacterial taxa enriched in inflammatory bowel diseases and colorectal cancer (CRC) are found in the oral cavity. We conducted a pilot study nested within a six-week aspirin intervention in a randomized placebo-controlled trial to test their response to aspirin intervention. Fifty healthy subjects, 50–75 years old, were randomized to receive 325 mg aspirin (n = 30) or placebo (n = 20) orally once daily for six weeks. Oral tongue swabs were collected at baseline and week six. We estimated the association between aspirin use and the temporal changes in the relative abundance of pre-specified genus level taxa from pre- to post-treatment. The temporal change in relative abundance differed for eight genus level taxa between the aspirin and placebo groups. In the aspirin group, there were significant increases in the relative abundances of Neisseria, Streptococcus, Actinomyces, and Rothia and significant decreases in Prevotella, Veillonella, Fusobacterium, and Porphyromonas relative to placebo. The log ratio of Neisseria to Fusobacterium declined more in the aspirin group than placebo, signaling a potential marker associated with aspirin intervention. These preliminary findings should be validated using metagenomic sequencing and may guide future studies on the role of aspirin on taxa in various oral ecological niches.
Successful treatment of PD1-inhibitor induced psoriasiform dermatitis using IL-17 blockade without compromising immunotherapy efficacy
Greene, Adina , Penner, Scott, Edmond, Amanda, Camou, Monica, Niu, Jiaxin , Abbott, Jordan K.

Journal of Oncology Pharmacy Practice | August 7, 2024 | Volume: 30 | Issue: 8 | Pages: 1450-1454

10.1177/10781552241269712 | PMID 39109556 Get It

Introduction Pembrolizumab is a monoclonal PD-1 inhibitor used in the treatment of lung cancer in addition to several other malignancies. Psoriasiform dermatitis is a well-documented adverse effect. Case report We present a 68 year-old-male with a 50-year smoking history and a 30-year remote history of plaque psoriasis, limited to the knees and elbows, who presented with metastatic non-small cell lung cancer. He was started on a chemotherapy regimen of carboplatin, paclitaxel, and pembrolizumab. One month later, he presented to dermatology with diffuse erythematous scaly papules coalescing into plaques on 80% of body surface area (BSA). Management & outcome Pembrolizumab treatment was paused. The patient was prescribed triamcinolone 0.1% twice daily, but still had significant BSA at one-month and was started on an Il-17 inhibitor, ixekizumab, clearing the psoriasiform dermatitis. He was rechallenged with pembrolizumab every 3 weeks and repeat PET/CT demonstrated excellent tumor response. Discussion This case prompted a literature review to further characterize the use of IL-17 inhibitors for psoriasiform dermatitis in the setting of ICI therapy. All six cases demonstrated improvement of psoriasiform dermatitis, with two cases showing partial response and four cases showing complete resolution. In three of the six cases, the patients exhibited clinical response to the primary malignancy after rechallenging with ICI, while remaining on an IL-17 inhibitor. Our case, in conjunction with the other reported cases, seems to suggest that IL-17 blockade can maintain a fine balance in this challenging clinical scenario by treating psoriasiform dermatitis without compromising the efficacy of immunotherapy.
Recommendations of the Blue Ribbon Committee II for the Optimization of Surgical Education and Training in the United States
Johnson, Wali R. , Mainali, Bigyan B. , Chen, Xiaodong, Martin, Rebecca , Dawson-Amoah, Kwesi G, Doyle, Kathleen M., Ellis, Danielle , Fazzone, Brian , Hoefer, Lea , Riner, Andrea N. , Shin, Thomas , Yelorda, Kirbi , Kearse, LaDonna , Chen, Xiaodong, Alobuia, Wilson Mawutor , Anderson, Erik M., Martin, Rebecca, Caldwell, Katharine E. , Dawson-Amoah, Kwesi G., Ghio, Michael , Godfrey, Caroline M. , Gomes, Camilla , Niehaus, Hannah, Phelps, Hannah M. , Sharon, Cimarron E. , Coleman, Julia R.

Annals of Surgery | August 7, 2024 | Volume: 281 | Issue: 1 | Pages: 40-45

10.1097/sla.0000000000006483 | PMID 39109446 Get It

Objective: This study aims to appraise recommendations from an expert panel of surgical educators on optimizing surgical education and training in the setting of contemporary challenges. Background: The Blue Ribbon Committee (BRC II), a group of surgical educators, was convened to make recommendations to optimize surgical training, considering the current changes in the landscape of surgical education. Surgical trainees were recruited to assess their impressions of the recommendations. Methods: A mixed-methods study design was employed, with a survey, followed by focus group interviews. Participating residents and fellows were recruited through a purposeful sampling approach. Descriptive statistics were applied to analyze the survey data, and a thematic data analysis on interview transcripts was employed. Results: The majority of trainee respondents (n=16) thought that all of the subcommittee recommendations should be included in the final BRC II recommendations and paper. According to the interviews, overall, the feedback from the trainees was positive, with particular excitement around work-life integration, education support and faculty development, and funding pitfalls. Some themes about concerns included a lack of clarity about the recommendations, concern about some recommendations being in conflict with one another, and a disconnect between the initial BRC II survey and the subsequent recommendations. Conclusions: The residents gathered for this focus group were encouraged by the thought, effort, and intention that gathered the surgical leaders across the country to make the recommendations. While the trainees wanted clarity on some areas, the overall opinion was in agreement with the recommendations.
Retrospective Review of Postpartum Lithium Use Including During Lactation
Kummerlowe, Megan N. , Kummer, Leslie , Moore, Katherine M. , Huppert, Rebekah L., Betcher, Hannah K. , Kummer, Leslie A , Leung, Jonathan G.

Breastfeeding Medicine | August 7, 2024 | Volume: 19 | Issue: 10 | Pages: 796-800

10.1089/bfm.2024.0101 | PMID 39109411 Get It

Introduction: Lithium remains a gold standard treatment for bipolar disorder including during peripartum. Historically, guidelines advised against breastfeeding while taking lithium though recent data suggest it is acceptable for a healthy infant. Lack of awareness of acceptability contributes to decreased patient and clinician comfort and low breastfeeding rates. We report current breastfeeding rates, monitoring practices, and infant outcomes with lithium exposure in breastmilk at our institution. Methods: A retrospective chart review was conducted at a single academic medical center using records from 2013 to 2023. Electronic medical records were queried to identify patients prescribed lithium postpartum. Data were collected on timing of lithium initiation, lithium dose and concentration, breastfeeding status, and infant outcomes. Results: A total of 18 cases of lithium use in the postpartum period were identified. A total of 39% ( n = 7) of patients taking lithium postpartum breastfed. Most patients, 61% ( n = 11), initiated lithium prior to pregnancy, 11% ( n = 2) initiated during pregnancy and 27% ( n = 5) started postpartum. Four infant charts were reviewed with no reports of adverse events. Of these infants, average maternal lithium dose was 750 mg daily, with an average maternal serum lithium concentration of 0.62 mmol/L and average infant serum lithium concentration of 0.16 mmol/L. Conclusion: Our data demonstrate most patients using lithium postpartum have been taking lithium long-term and are not breastfeeding. Lithium exposure in breastmilk appears to be tolerated by healthy infants. There is a need for ongoing research and education on acceptability and infant monitoring recommendations to support patients who would like to breastfeed while on lithium.
Persistent indurated plaques involving the forehead and vulva
Witter, Taylor L. , Jing, Frank Z. , Aghazadeh, Nessa , Aghazadeh Mohandesi, Nessa , Jing, Frank Z

International Journal of Dermatology | August 7, 2024 | Volume: 63 | Issue: 11 | Pages: 1525-1527

10.1111/ijd.17421 | PMID 39107917 Get It

AbstractA 61‐year‐old female presented with progressive plaques on the left forehead and right labia.
Advancements and Challenges in Artificial Intelligence-Driven Diagnosis and Management of Pancreatic Cancer
Oza, Veeral M. , Antony, Ajith , Mukherjee, Sovanlal , Goenka, Ajit H. , Mittal, Nitish

AI in Precision Oncology | August 7, 2024 | Volume: 1 | Issue: 4 | Pages: 207-215

10.1089/aipo.2024.0032 Get It

Pancreatic cancer (PC), characterized by a dismal 5-year survival rate of approximately 12%, remains one of the most aggressive cancers. Majority of cases are identified at advanced stages, which are beyond the scope of surgical resection. Importantly, while the overall prognosis for PC is poor, localized stages of the disease can significantly enhance survival chances because of the potential for curative interventions. We explore the evolution of early detection strategies, including screening methods for high-risk individuals, the yield of diagnostic tests, and the impact of emerging technologies. Special emphasis is given to the role of artificial intelligence in overcoming the limitations of standard imaging practices, thereby refining diagnostic accuracy, and predicting patient outcomes. Our review synthesizes current controversies and addresses the technological advancements that could potentially shift the paradigm toward improved survival rates for patients with PC.
Evaluating cell type deconvolution in FFPE breast tissue: application to benign breast disease
Liu, Yuanhang , Bhagwate, Aditya , Jons, William , McCauley, Bryan M. , Stephens, Melissa, Littlepage, Laurie E. , Cunningham, Julie M. , Jons, William A, Stallings-Mann, Melody L, Radisky, Derek C. , Cunningham, Julie M , Wang, Chen , Vierkant, Robert A. , Stallings‐Mann, Melody , Carter, Jodi M. , Pfrender, Michael E. , Degnim, Amy C. , Winham, Stacey J. , Wang, Chen

NAR Genomics and Bioinformatics | August 7, 2024 | Volume: 6 | Issue: 3 | Pages: No page available

10.1093/nargab/lqae098 | PMID 40162103 Get It

Abstract Transcriptome profiling using RNA sequencing (RNA-seq) of bulk formalin-fixed paraffin-embedded (FFPE) tissue blocks is a standard method in biomedical research. However, when used on tissues with diverse cell type compositions, it yields averaged gene expression profiles, complicating biomarker identification due to variations in cell proportions. To address the need for optimized strategies for defining individual cell type compositions from bulk FFPE samples, we constructed single-cell RNA-seq reference data for breast tissue and tested cell type deconvolution methods. Initial simulation experiments showed similar performances across multiple commonly used deconvolution methods. However, the introduction of FFPE artifacts significantly impacted their performances, with a root mean squared error (RMSE) ranging between 0.04 and 0.17. Scaden, a deep learning-based method, consistently outperformed the others, demonstrating robustness against FFPE artifacts. Testing these methods on our 62-sample RNA-seq benign breast disease cohort in which cell type composition was estimated using digital pathology approaches, we found that pre-filtering of the reference data enhanced the accuracy of most methods, realizing up to a 32% reduction in RMSE. To support further research efforts in this domain, we introduce SCdeconR, an R package designed for streamlined cell type deconvolution assessments and downstream analyses.
Intra-arterial Melphalan as Targeted Therapy for Tumefactive Multiple Sclerosis Lesions
Banks, Samantha A. , Brinjikji, Waleed , Xeros, Helena K., Toledano, Michel , Carabenciov, Ivan D. , Banks, Samantha , Giannini, Caterina , Syc‐Mazurek, Stephanie B. , Xeros, Helena , Mustafa, Rafid , Tobin, W. Oliver

Neurology | August 6, 2024 | Volume: 103 | Issue: 5 | Pages: No page available

10.1212/wnl.0000000000209739 | PMID 39106425 Get It

Advancing Care Team Adoption of Electronic Health Record Systems for Cancer Symptom Management: Findings From a Hybrid Type II, Cluster-Randomized, Stepped-Wedge Trial
Austin, Jessica D. , Fischer, Kristin , Ridgeway, Jennifer L. , Minteer, Sarah A. , Griffin, Joan M. , Pachman, Deirdre R. , Ruddy, Kathryn J. , Cheville, Andrea , Fischer, Kristin , Ridgeway, Jennifer L , Redmond, Sarah , Griffin, Joan M , Ruddy, Kathryn J , Cheville, Andrea L , Austin, Jessica D , Rutten, Lila J. Finney

JCO Oncology Practice | August 6, 2024 | Volume: 21 | Issue: 2 | Pages: 209-217

10.1200/op.24.00280 | PMID 39106420 Get It

PURPOSE The enhanced, electronic health record (EHR)–facilitated cancer symptom control (E2C2) trial is a cohort cluster-randomized, stepped-wedge, hybrid type II trial that leverages EHR systems to facilitate a collaborative care model (CCM) approach with the goal of improving cancer symptom management. Understanding factors that influence care team adoption of EHR systems remains a critical understudied area of research. This study examines how oncology care teams' perceptions regarding the feasibility, acceptability, and appropriateness of E2C2 EHR systems preimplementation were associated with adoption 3 months after implementation and characterizes differences in adoption by individual- and system-level factors. METHODS Care team members completed an electronic survey before and 3 months after implementation of E2C2 for their respective sequence. Adoption was defined as frequency of use to statements aligned with care team–directed EHR systems designed to facilitate CCM approaches. Chi-square tests assessed differences in adoption while logistic regression models estimated associations between baseline mean scores of acceptability, feasibility, and appropriateness on care team adoption at 3 months. RESULTS Results from 94 care team members (37.2% oncologists, 72.6% female, 55.3% in their role for 6+ years) found that adoption rates ranged from 48.9% to 71.7%, with significant differences observed by location (community-based health care systems v tertiary medical center) and professional role. Adjusting for professional role, care team members reporting higher levels of perceived acceptability and appropriateness at baseline had greater odds of adopting EHR systems at 3 months. CONCLUSION EHR systems perceived as acceptable and appropriate are more likely to be adopted by oncology care teams in our sample. Future implementation efforts should consider tailored strategies to facilitate adoption of EHR systems designed to promote CCM-based approaches to improve cancer symptom management.